Literature DB >> 1589765

Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.

E P Wiertelak1, S F Maier, L R Watkins.   

Abstract

Environmental stimuli that signal the occurrence of aversive or dangerous events activate endogenous opiate analgesia systems. Signals for safety (the nonoccurrence of aversive events) produce the opposite and inhibit environmentally produced analgesia. Stimuli that signal safety are now shown to abolish the analgesic effect of morphine, even when morphine is applied directly to spinal cord. Further, this antiopiate effect occurs because the environmental stimulus leads to release of the neuropeptide cholecystokinin in the spinal cord. This process may contribute to the regulation of pain and the development of opiate tolerance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589765     DOI: 10.1126/science.1589765

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  20 in total

1.  Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor.

Authors:  F Porreca; S E Burgess; L R Gardell; T W Vanderah; T P Malan; M H Ossipov; D A Lappi; J Lai
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  [Is the analgesic effect of acupuncture a placebo effect?].

Authors:  F Musial; I Tao; G Dobos
Journal:  Schmerz       Date:  2009-08       Impact factor: 1.107

Review 3.  Inhibition of fear by learned safety signals: a mini-symposium review.

Authors:  John P Christianson; Anushka B P Fernando; Andy M Kazama; Tanja Jovanovic; Linnaea E Ostroff; Susan Sangha
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

4.  It's Time to Listen to the Dummy What It Means When the Modest Placebo Speaks.

Authors:  Walter Alexander
Journal:  P T       Date:  2017-11

5.  Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole.

Authors:  M Derrien; C Durieux; B P Roques
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

6.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

Authors:  M Poncelet; M Arnone; M Heaulme; N Gonalons; C Gueudet; V Santucci; O Thurneyssen; P Keane; D Gully; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

8.  Cholecystokinin peptides and receptors in the rat brain during stress.

Authors:  J Harro; C Löfberg; J F Rehfeld; L Oreland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

9.  Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.

Authors:  K Lutfy; D Parikh; D L Lee; Y Liu; M G Ferrini; A Hamid; T C Friedman
Journal:  Neuroscience       Date:  2016-05-18       Impact factor: 3.590

10.  Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors.

Authors:  Alar Veraksits; Kertu Rünkorg; Kaido Kurrikoff; Sirli Raud; Urho Abramov; Toshimitsu Matsui; Michel Bourin; Sulev Kõks; Eero Vasar
Journal:  Psychopharmacology (Berl)       Date:  2003-01-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.